Key result
Intensive BP control cuts major CV events by ~40% across PREVENT cardiovascular risk tiers.
Why the study?
The 2025 AHA/ACC guideline adopted the PREVENT equations to guide antihypertensive treatment, but whether PREVENT risk groups identify patients who benefit more from intensive BP control remained uncertain.
Does intensive blood pressure control (target <130/80 mm Hg) reduce major cardiovascular events and improve life expectancy across different PREVENT risk groups in rural Chinese adults with hypertension?
RCT (n=21,872)
Yes
Does intensive blood pressure control (target <130/80 mm Hg) reduce major cardiovascular events and improve life expectancy across different PREVENT risk groups in rural Chinese adults with hypertension?
Intensive blood pressure lowering (<130/80 mm Hg) provides favorable net clinical benefit across all PREVENT risk strata in rural hypertensive patients, with the largest absolute benefits and life expectancy gains (1.26 years at age 45) in the high-risk group.
Answers are grounded in this paper and cite their sources.
PREVENT stratification may not guide intensive BP targets in rural hypertension; leaves open need for prospective validation before adoption.
BACKGROUND: The 2025 American Heart Association/American College of Cardiology guideline adopted the Predicting Risk of Cardiovascular Disease Events (PREVENT) equations to guide antihypertensive treatment, but whether PREVENT risk groups identify patients who benefit more from intensive blood pressure (BP) control is uncertain. We evaluated intensive BP control across PREVENT risk groups in the China Rural Hypertension Control Project. METHODS: We analyzed 21 872 hypertensive adults from 326 Chinese villages. Participants received intensive BP control (target <130/80 mm Hg) or usual care and were classified as low risk (<5%), borderline risk (5.0%-7.4%), intermediate risk (7.5%-19.9%), or high risk (≥20%). The primary outcome was a composite of major cardiovascular events (myocardial infarction, stroke, heart failure, or cardiovascular death). Safety, net benefit, and life expectancy were assessed. RESULTS: Over a median of 3.02 years, intensive BP control was associated with lower cardiovascular risk in the low-risk (hazard ratio, 0.53 [95% CI, 0.29-0.97]), intermediate-risk (hazard ratio, 0.58 [95% CI, 0.49-0.69]), and high-risk groups (hazard ratio, 0.60 [95% CI, 0.47-0.77]), but not the borderline-risk group (hazard ratio, 0.80 [95% CI, 0.51-1.26]). No significant treatment-by-risk interaction was observed. Adverse events increased mainly in intermediate- and high-risk groups. Net benefit was favorable across all groups and greatest in the high-risk group. At 45 years of age, estimated life expectancy gains were 0.94 years overall, 0.71 years in the intermediate-risk group, and 1.26 years in the high-risk group. CONCLUSIONS: Intensive BP control was associated with lower cardiovascular risk in 3 PREVENT risk groups, with favorable net benefit across all groups. Absolute benefit and estimated life expectancy gains were greatest among high-risk participants. PREVENT risk stratification may inform intensive BP control in community-based hypertensive populations.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) conducted an RCT in Hypertension (n=21,872). Intensive blood pressure control (target <130/80 mm Hg) vs. Usual care was evaluated on Composite of major cardiovascular events (myocardial infarction, stroke, heart failure, or cardiovascular death) (HR 0.60 (high-risk group); HR 0.58 (intermediate-risk); HR 0.80 (borderline-risk); HR 0.53 (low-risk), 95% CI 0.47-0.77 (high-risk); 0.49-0.69 (intermediate-risk); 0.51-1.26 (borderline-risk); 0.29-0.97 (low-risk)). Intensive BP control (<130/80 mm Hg) reduced major CV events in low, intermediate, and high PREVENT risk groups, with greatest life expectancy gain in high risk.
Synapse has enriched 10 related papers. Consider them for comparative context: